Record YoY Growth Masks Sequential Slide; Execution Risk Rises

The headline is one of the strongest the CDMO sector has seen this year. Revenue up 119% YoY, profit up 962%. On the surface, it reads like the quarter management promised—the payoff on peptide capex, customer partnerships, and long-term positioning. But step past the headline and the call tells a different story: management withheld guidance for FY27, deliberately reset EBITDA margin expectations downward by 10 percentage points, and chose careful language on lumpiness. The market caught the YoY pop and drove the stock +7.95% on day 1 post-announcement; the call explains why that pop may have outrun the fundamentals.

Q4 FY26 was exceptional—management disclosed that it benefited from Q3 spillovers, making it a peak-out quarter. Q1 FY27 normalizes from that artificial high, landing –17.3% down. YoY it looks blockbuster because Q1 FY26 was a trough (₹293 Cr revenue, ₹13.7 Cr PAT). The PAT comp is even more extreme: +962% YoY, but from a near-zero base in the prior year. The operating leverage is real—NPM expanded to 22.7% and OPM to 34.7%—but the Q1 print is not a steady-state run-rate. It is a peak.

Peptide platform validation. Two years ago this was internal conviction only. Now, pre-commissioning (Sept 2026), customer interest is expanding and projects are converting. CEO signaled comfort that market demand is real, not hypothetical. Development pipeline inflection. Two new advanced-stage projects entered Q1; some are peptide-based. CEO stated comfort level on pipeline quality has improved over 1–2 years. This directly addresses the near-term risk of customer concentration on 3 CMS molecules. Capex ambition raised. ₹203 Cr approved this quarter (₹121.6 Cr spent in Q1 alone). Full program ₹1,460 Cr, 60% deployed. CEO called forward capex "much higher" than historical pace, signaling bold moves on geographic diversification and scale. Margin expectations reset. EBITDA margin guided down to 25% normalized (vs. current 35.5% boosted by FX). This is a deliberate walk-back, signaling management expects margin compression from current levels as the FX tailwind fades or mix normalizes.

Working capital improved sharply: 84 days at Q1 FY27 vs. 137 days at FY26 end—a 53-day improvement. This reflects disciplined inventory and receivables management and strong cash conversion from the higher-margin CMS business.

Leadership is transparent on strategy and long-term vision but deliberately cautious on near-term specifics. No FY27 revenue or margin guidance given—despite analyst pressure for it. CEO explicitly emphasized that lumpiness is inherent to the CMS business model and that Q1 is not a repeatable run-rate. He also stated that many development pipeline projects remain in clinical development and relationships with new customers are "relatively new." This is credible risk disclosure, not cheerleading. Management chose to prioritize credibility over optimism, a positive signal.

Price action and technicals. The day-1 pop of +7.95% post-announcement held and the stock now trades at ₹22,216. It sits –5.33% off its all-time high (₹23,467), confirming the market has absorbed the print. Volume is increasing, a bullish signal. But RSI is 71.4 (overbought), indicating the rally has extended from technicals rather than fundamentals alone. The stock is above all major moving averages (SMA20 ₹19,495, SMA50 ₹18,502, SMA200 ₹15,819), a steady uptrend—but stretched. Institutional flows. FII ownership at 21.08% (up 0.62pp QoQ), DII at 16.51% (up 0.67pp QoQ). Both are accumulating. Bulk deal activity shows HDFC Mutual Fund bought 64,547 shares @ ₹21,585, signaling institutional confidence at current levels. No insider selling or promoter trimming near the highs—a positive signal. The tension. Institutions are adding to the stock, but management withheld guidance and reset margin expectations. The market is betting on the 20% growth aspiration; management is hedging on it. This divergence is the call's real message: the street is positioned optimistic, but management is positioned cautious.